Pharmafile Logo
Pharmafocus logo
Advanced Search

sales

Showing 15 posts of 91 posts found.

v2_crestor_10_mg

Allergan launches Crestor generic in the US

May 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …

News
mylan_building

Mylan Q1 revenue up 17%, maintains FY view

May 3, 2016
Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales

Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …

News
gsk-house-location-building

GlaxoSmithKline Q1 earnings up 14% on new product sales

April 27, 2016
Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales

GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …

News
headquarters_3_web

Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%

April 27, 2016
Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales

Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …

News
ironwood_pharma

AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals

April 27, 2016
Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales

AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …

News
credit_bayerag

Bayer’s earnings beat estimates as blockbusters shine

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales

Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …

News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016
Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …

Feature
jj_sign_on_wall

J&J raises FY outlook, Q1 beats estimates

April 20, 2016
Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …

News
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016
Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

News
Merck image

Revenues down at MSD

February 4, 2016
Sales and Marketing MSD, financial performance, profits, revenue, sales

MSD (Merck, Sharpe and Dohme) reported a mixed bag of financial figures today, as the company announced full-year 2015 revenues …

News
pills-943764_1920

Revealed: analysts predict seven highest-earning pharma blockbusters

February 4, 2016
Sales and Marketing Gilead, OCA, Thomson Reuters, blockbusters, sales

Seven new drugs currently in development will enter the market this year – and earn sales of more than $1 …

News

Pfizer revenues down, but above expectations

February 3, 2016
Research and Development, Sales and Marketing Ian Read, Pfizer, financial results, income, profits, revenue, sales

Pfizer’s revenues took a hit from generic competition on former blockbusters, but the world’s new largest drugmaker still managed to …

News
Joseph Jimenez

Novartis braces for cuts after mixed 2015 performance

January 28, 2016
Sales and Marketing Novartis, financial results, revenue, sales

Net sales at Novartis fell by 5% in 2015 – prompting the company to make billion-dollar changes to its business …

News

Johnson & Johnson hit by fall in 2015 sales

January 27, 2016
Research and Development, Sales and Marketing Janssen, Johnson and Johnson, financial results, revenue, sales

Full year sales at the healthcare giant Johnson & Johnson fell by 6% in 2015, to just over $70 billion, …

News
Takeda UK

Takeda to bring UK salesforce in-house

January 15, 2016
Medical Communications, Sales and Marketing Takeda, field sales, marketing, sales, sales reps, salesforce

Takeda UK is to bring all of its sales teams and support resources in-house and reintegrate its field salesforce into …

News
The Gateway to Local Adoption Series

Latest content

NICE backs atogepant for acute migraine treatment

June 12, 2026

Survey data highlight challenges in anaphylaxis treatment adherence

June 11, 2026

Hansa Biopharma appoints Fredrik Röök as VP Business Development

June 11, 2026

Sofinnova and AWS collaborate on AI tools for life sciences

June 10, 2026

First European approval given to non-opioid treatment for chronic low back pain

June 9, 2026